Is There a Role for MRD-Response Adapted Therapy in Transplant-Eligible NDMM?
Dr Ajay Nooka describes key data from the uniquely-designed MASTER trial investigating daratumumab in combination with carfilzomib, lenalidomide and dexamethasone (Dara-KRd) versus KRd in transplant-eligible newly diagnosed multiple myeloma.
EP: 1.Frontline Treatment Options for Transplant-Ineligible Newly Diagnosed Multiple Myeloma
EP: 2.Comparison of Results from the MAIA and SWOG0777 Studies
EP: 3.Triplet vs Doublet Induction Therapy for Transplant-Ineligible MM and Role of Real-World Evidence
EP: 4.Treatment Decision-Making Based on Real-World Data in Transplant-Ineligible NDMM
EP: 5.Maintenance Therapy in Transplant-Ineligible Multiple Myeloma
EP: 6.Determining Treatment Duration for Transplant-Ineligible Multiple Myeloma
EP: 7.Unmet Needs of Transplant-Ineligible Multiple Myeloma
EP: 8.Racial Disparities in the Treatment of Multiple Myeloma Patients
EP: 9.Comparing Combination Treatment Regimens in Transplant-Eligible NDMM
Now Viewing
EP: 10.Is There a Role for MRD-Response Adapted Therapy in Transplant-Eligible NDMM?
EP: 11.The GMMG HD7 Trial of Isa-VRd vs VRd in Transplant-Eligible NDMM
EP: 12.Treatment Decision-Making Based on Clinical Trial Data in Transplant-Eligible NDMM
EP: 13.Treatment Decision-Making Based on Real-World Data in Transplant-Eligible NDMM
EP: 14.Measuring Treatment Response in Transplant-Eligible NDMM after Induction Therapy
EP: 15.Recap: Recent Advances in Multiple Myeloma: Applying Real-world Evidence to Clinical Practice
EP: 16.Determining Treatment Duration for Transplant-Eligible NDMM
EP: 17.Racial Disparities in Presentation, Diagnosis, and Treatment of MM
EP: 18.Unmet Needs and Future Perspectives in Transplant-Eligible NDMM
EP: 19.Characterization and Management of High-Risk Patients with MM
Recent Videos
Related Content
Administering CAR T-Cell Therapy and Bispecific Agents in Nursing Practice
Ishmael Applewhite, BSN, RN-BC, OCN;Leslie Bennett, MSN, RN;Kathy Mooney, MSN, RN, ACNS-BC, BMTCN®, OCN®
May 6th 2024Podcast
Registered nurses discuss research related to agents like ciltacabtagene autoleucel presented at the 2024 Oncology Nursing Society Congress.
Evaluating the Use of CAR T-Cell Therapy for Multiple Myeloma in Academic and Community Settings
August 27th 2024Article
Strategies for treating patients with multiple myeloma who are eligible to receive CAR T-cell therapy in either community or academic practices were discussed in a recent Training Academy.
